BUZZ-Verastem Oncology falls on planned stock offering

Reuters

Nov 14

BUZZ-<a href="https://laohu8.com/S/VSTM">Verastem</a> Oncology falls on planned stock offering

** Verastem's VSTM.O shares down 6.2% in extended trading to $7.61 after equity offering news

** Needham, Massachusetts-based VSTM announces stock offering without disclosing deal size

** It intends to use net offering proceeds to fund commercial activities for its U.S. FDA approved ovarian cancer therapy, branded as Avmapki Fakzynja Co-pack, continued R&D of other product candidates, among other purposes

** Jefferies, Guggenheim and Cantor Fitzgerald are joint bookrunners

** VSTM has ~66.8 mln shares outstanding for about $542 mln market cap

** Shares on Thurs finished down 4.7% at $8.11, trimming YTD gain to 57%

** All 9 analysts covering VSTM are bullish and their median PT is $15.50, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2583121985"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583121985\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583121985?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583121985","market":"us","top_or_hot":-1,"title":"BUZZ-Verastem Oncology falls on planned stock offering","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology falls on planned stock offering</title></head><body><p>\n    ** Verastem's <span>VSTM.O</span> shares down 6.2% in extended trading to $7.61 after equity offering news\n  </p><p>\n    ** Needham, Massachusetts-based VSTM announces stock offering without disclosing deal size\n  </p><p>\n    ** It intends to use net offering proceeds to fund commercial activities for its U.S. FDA approved <span>ovarian cancer therapy</span>, branded as Avmapki Fakzynja Co-pack, continued R&amp;D of other product candidates, among other purposes</p><p>** Jefferies, Guggenheim and Cantor Fitzgerald are joint bookrunners</p><p>** VSTM has ~66.8 mln shares outstanding for about $542 mln market cap</p><p>** Shares on Thurs finished down 4.7% at $8.11, trimming YTD gain to 57%</p><p>\n    ** All 9 analysts covering VSTM are bullish and their median PT is $15.50, per LSEG data\n  </p><p>(Lance Tupper is a Reuters market analyst. The views expressed are his own)</p><p>((lance.tupper@tr.com 1-646-279-6380))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Verastem Oncology falls on planned stock offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Verastem Oncology falls on planned stock offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology falls on planned stock offering</title></head><body><p>\n    ** Verastem's <span>VSTM.O</span> shares down 6.2% in extended trading to $7.61 after equity offering news\n  </p><p>\n    ** Needham, Massachusetts-based VSTM announces stock offering without disclosing deal size\n  </p><p>\n    ** It intends to use net offering proceeds to fund commercial activities for its U.S. FDA approved <span>ovarian cancer therapy</span>, branded as Avmapki Fakzynja Co-pack, continued R&amp;D of other product candidates, among other purposes</p><p>** Jefferies, Guggenheim and Cantor Fitzgerald are joint bookrunners</p><p>** VSTM has ~66.8 mln shares outstanding for about $542 mln market cap</p><p>** Shares on Thurs finished down 4.7% at $8.11, trimming YTD gain to 57%</p><p>\n    ** All 9 analysts covering VSTM are bullish and their median PT is $15.50, per LSEG data\n  </p><p>(Lance Tupper is a Reuters market analyst. The views expressed are his own)</p><p>((lance.tupper@tr.com 1-646-279-6380))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4127","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL6N3WP179:1","article_id":"2583121985","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583121985","pubTimestamp":1763069352,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"** Verastem's VSTM.O shares down 6.2% in extended trading to $7.61 after equity offering news. ** Needham, Massachusetts-based VSTM announces stock offering without disclosing deal size. ** It intends to use net offering proceeds to fund commercial activities for its U.S. FDA approved ovarian cancer therapy, branded as Avmapki Fakzynja Co-pack, continued R&D of other product candidates, among other purposes** Jefferies, Guggenheim and Cantor Fitzgerald are joint bookrunners** VSTM has ~66.8 mln shares outstanding for about $542 mln market cap** Shares on Thurs finished down 4.7% at $8.11, trimming YTD gain to 57%. ** All 9 analysts covering VSTM are bullish and their median PT is $15.50, per LSEG data","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4127":"投资银行业与经纪业","BK4559":"巴菲特持仓","JEF":"杰富瑞","VSTM":"Verastem","BK4139":"生物科技"},"translate_title":"BUZZ-Verastem Oncology计划股票发行失败","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":0.9,"JEF":0.9},"content_text":"BUZZ-Verastem Oncology falls on planned stock offering\n    ** Verastem's VSTM.O shares down 6.2% in extended trading to $7.61 after equity offering news\n  \n    ** Needham, Massachusetts-based VSTM announces stock offering without disclosing deal size\n  \n    ** It intends to use net offering proceeds to fund commercial activities for its U.S. FDA approved ovarian cancer therapy, branded as Avmapki Fakzynja Co-pack, continued R&D of other product candidates, among other purposes** Jefferies, Guggenheim and Cantor Fitzgerald are joint bookrunners** VSTM has ~66.8 mln shares outstanding for about $542 mln market cap** Shares on Thurs finished down 4.7% at $8.11, trimming YTD gain to 57%\n    ** All 9 analysts covering VSTM are bullish and their median PT is $15.50, per LSEG data\n  (Lance Tupper is a Reuters market analyst. The views expressed are his own)((lance.tupper@tr.com 1-646-279-6380))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}